November 2022

Today's challenges are tomorrow's opportunities


George Saffaye, Global Investment Strategist



For Professional Investors only. Provided for information purposes only to members of the financial press > BNY MELLON | INVESTMENT MANAGEMENT


NEWION The Pace of Innovation & Disruption is Accelerating at an Unprecedented Rate

Investment Management



Source: NIMNA, Population Connection. Note: Population data post 2016 based on projections. NIMNA has reviewed the above research and believes the findings are still valid even without the inclusion of more recent data.

The Pace of Innovation & Disruption is Accelerating at an Unprecedented Rate The Road to Ubiquity is Getting Shorter




NEWION Investment Must Reflect the Realities of a Changing World

Whether through acquisition, bankruptcy, or other means, average company life spans have dropped sharply

Average Company Lifespan on S&P 500[®] Index

Investment Managemen



NEWION The Shift From Industry 1.0 To 4.0 Has Taken Over 300 Years

Industry 5.0 is expected to digitalize the entire manufacturing ecosystem


Investment Management

	Revolution	Theme	Key Features
٢٢)	Industry 1.0	Mechanical Production	 Mechanical production powered by water and stream power Timeframe: End of 18th Century
999	Industry 2.0	Mass Production	 Introduction of assembly lines and use of electrical energy Introduction of telegraphy in 1840 and telephony in 1880 Ford used 'Taylorism'² to implement care assembly line Timeframe: Beginning of 20th Century
Š	Industry 3.0	Application of IT	 Use of electronics, IT, and industrial robotics to improve automation of production First micro-computer in 1971 Apple founded in 1976 Timeframe: Start of 1970s
Ŀ	Industry 4.0	Cyber-physical production systems	 Digital supply chain Digital products, service, and new business models Autonomous machines and virtual environments Timeframe: 2010 - 2030
	Industry 5.0	Complete digital ecosystem	 Virtual customer interface and virtualized processes Flexible, virtual, and integrated value chain networks Completely connect ecosystems Timeframe: 2030 onwards

Source: Statista, "In-Depth: Industry 4.0 2021, Statista Digital Market Outlook" -- published June 2021, 1Taylorism - Named after the U.S. industrial engineer Frederick Winslow Taylor, this theory laid down the fundamental principles of large scale manufacturing through assembly line factories. NIMNA Modifications.

NEWION Innovation Driven Opportunities

Investment Management



NEWION Digitalization and New Technologies

Investment Management

	Digitalization Activities	Key Technologies
····	Collect, store and transmit data	 Sensors and tracking (e.g. RFID) Communications interface & standards, 5G Cloud-based storage and service models
	Analyze data	 Predictive Analytics Product life management (PLM) software
	Interact with data	 Virtual reality Mobile/Tablet/Watch Visualization tools (e.g. Tableau) Crowdsourcing (e.g. sentiment analysis)
Ś	Product digitally	 Addictive manufacturing techniques (e.g. 3D printing) Advanced Robotics MES software
\bigcirc	Protect data	 Cybersecurity & digital trust Blockchain






MOBILITY INNOVATION


Mobility Innovation is the disruptive, transformational shift in how we use, power and control all means of mobility. It profoundly impacts businesses, governments and consumers by materially altering interactions across the mobility landscape.

NEWION Catalysts for Mobility Innovation

investment Management







Source: Bottom Left: McKinsey Center for Future Mobility (Sep. 2017). Bottom Right: Bloomberg New Energy Finance as of May 21, 2018. NIMNA has reviewed the above research and believes the findings are still valid even without the inclusion of more recent data.



BLOCKCHAIN INNOVATION

Blockchain Innovation encompasses the diversified use of distributed ledger technology (synonymously known as blockchain technology) – a software that permits the creation of provable and immutably unique digital fingerprints. At its core, this breakthrough capability protects against duplication in the digital age, representing a transformational shift in trust-dependent ecosystems.

0



INCREASES

Revenues



- Customer Experience
- Secondary Markets
- Speed
- Real Time

) • Se

- Security
 - Immutable & Encrypted

Transparency

REDUCES

Costs



- Process Efficiency
- Reduce Waste
- Eliminate Redundancies

Fraud

- Secure Transactions
- Permanent Records
- Risk
 - De-centralized
 - No single point failure









Focus: Transfer of goods, services & data

Optimize business processes and data, enhance cybersecurity, and minimize/eliminate the roles of intermediaries across and beyond the enterprise.

Examples: Shipping/Logistics Supply Chains Cyber Security

TOKENIZED ASSETS



Focus: Transfer of physical assets

Greater liquidity, transparency, and accessibility with faster and cheaper transactions than existing markets.

FINANCIAL SYSTEMS



Focus: Transfer of value

Faster execution and settlement than traditional trades, reduced costs, increased accessibility, operational simplification, and automated compliance.

Examples: Real Estate Carbon credits Collectibles

- Examples Insurance
- Payments Lending



SMART CURES INNOVATION

Smart cures treat diseases by targeting the underpinning genetics that drive those diseases. We believe this new class of drugs will provide functional cures for many diseases over the next decade, sometimes with as little as a single dose. The Smart Cures Innovation strategy encompasses companies that are developing gene therapy, gene editing and gene modulation, as well as the supporting companies that help fuel the development of these drugs. These treatments are powered by remarkable advancements in science and represent some of the most potent drugs seen to date.

The BIG Picture of the Smart Cures Innovation Technologies

Gene Tech can theoretically make every protein in the human body "druggable" creating an enormous whitespace of opportunity

Targetable Proteins in Human Body

~100% MONOCLONAL ANTIBODIES (Ex. Injectable Proteins) Biotech 1.0 drugs Expands protein targets Extra-cellular Ex. Rheumatoid Arthritis. Psoriasis, and many Cancer ~25% ~15% Traditional Small Monoclonal Gene Technology Molecules Antibodies

TRADITIONALSMALL MOLECULES

(Ex. Pills)

Investment Management

- Historical drugs
- Limited disease treatment capabilities
- Extra-cellular
- Ex. Cholesterol. Diabetes. and High Blood Pressure pills
- Timeline: Last 150 years
- Therapies • Timeline: 1990's to today

GENE TECHNOLOGY

(Ex. Classical Gene Therapy, Cell-Based Therapy, RNA-Based Therapy, Genomic Guided Treatments & Gene Editing)

٠

٠

٠


.

- Biotech 2.0
- Potential to address and CURE every human disease at its source
- Intra-cellular
- Enhanced by the power of Genomics, Proteomics and Artificial Intelligence
- Ex. Rare Diseases (DMD), Cancer (Leukemia), Common Diseases (Diabetes)
- Timeline: Today

NEWTON Why Now? Target Market Sizes Are Very Large

Genetic Medicines target large un-met needs

Investment Managemen



NEWION Current Investment Themes

investment Management



Bio-Physical Economy Blockchain Tokenization Creator Ecosystems Nuclear Renaissance Quantum Computing Regenerative Agriculture Synthetic Biology Virtual and Augmented Reality Virtual GRID Wearables



EMERGING

Advanced Manufacturing Agriculture Tech Artificial Intelligence Cannabis Climate Adaption Consumer Discovery De-Globalization Edge Computing Embedded Finance Enterprise Blockchain Factory Automation Gene Therapy Healthcare Delivery Household Formations Mobility Innovation Multiomics Smart Ecosystems Social Infrastructure Space Sports Betting



ESTABLISHED

5G Consumer Data Cyber Security Digital Transformation Fintech Frictionless Economy Healthcare Innovation Internet of Things Longevity Public Commercial Construction Residential Construction Sustainability



PAST

Activist Government Baby Boomers Commercial Aerospace Commodities Supercycle Construction Healthcare Reform Private Commercial Construction

Important information

For Professional Clients only. This is a financial promotion and is not investment advice.

Any views and opinions are those of the investment manager, unless otherwise noted, and is not investment advice.

BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation and its subsidiaries.

Issued in France, Belgium & Luxembourg by BNY Mellon Fund Management (Luxembourg) S.A. (BNY MFML), a public limited company (société anonyme) incorporated and existing under Luxembourg law under registration number B28166 and having its registered address at 2-4 Rue Eugène Ruppert L-2453 Luxembourg. BNY MFML is regulated by the Commission de Surveillance du Secteur Financier (CSSF).

For the press

Unless otherwise specified herein, all information sourced by BNY Mellon as of October 31st, 2022. This presentation is qualified for issuance in France and is for information purposes only. It does not constitute an offer or solicitation of securities or investment services or an endorsement thereof in any jurisdiction or in any circumstance in which such offer or solicitation is unlawful or not authorized. Any views and opinions contained in this document are those of the investment manager, unless otherwise noted. In France this presentation is used by BNY Mellon Fund Management (Luxembourg) S.A. (BNY MFML), to members of the financial press and media and the information contained herein should not be construed as investment advice. BNY MFML is a public limited company (société anonyme) incorporated and existing under Luxembourg law under registration number B28166 and having its registered address at 2-4 Rue Eugène Ruppert L-2453 Luxembourg. Regulated by the Commission de Surveillance du Secteur Financier (CSSF). A BNY Mellon Company

